Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Munich
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Ampio Pharmaceuticals Inc

+ Add to Watchlist

APH:GR

2.541 EUR 0.129 4.83%

As of 02:16:02 ET on 04/27/2015.

Snapshot for Ampio Pharmaceuticals Inc (APH)

Open: 2.481 Day's Range: 2.481 - 2.541 Volume: 0
Previous Close: 2.670 52wk Range: 2.372 - 7.888 1-Yr Rtn: -38.93%

Stock Chart for APH

No chart data available.
  • APH:GR 2.541
  • 1D
  • 1M
  • 1Y
2.670
Interactive APH Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for APH

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2015) -
Est. PEG Ratio -
Market Cap (M EUR) 132.06
Shares Outstanding (M) 51.97
30 Day Average Volume 190
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/07/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for APH

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for APH

Ampio Pharmaceuticals, Inc. researches and develops drugs. The Company researches treatments for metabolic disease, eye disease, kidney disease, inflammation and CNS disease. The Company's product pipeline includes some new uses for previously approved drugs.

Michael Macaluso JrChairman/CEOGregory A GouldCFO/Treasurer/Secretary
David Bar-OrChief Scientific OfficerVaughan L CliftChief Regulatory Affairs Ofcr
More Company Profile & Key Executives for APH

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil